Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy ...

CPV-104 interim Phase 1 results support favorable safety and tolerability, with encouraging early efficacy trends in patients with C3 ...

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

Assessment of the Treatment Landscape, Epidemiology Insights, C3G Pipeline, Competitive Landscape, Market Drivers, Unmet Needs, Market Access, Pricing, and ReimbursementDublin, Sept. 08, 2026 (GLOBE ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

During a discussion on the next frontier of medicine for cold agglutinin disease, stakeholders react to the rationale for studying newer, novel complement-targeted therapies. Neil Minkoff, MD: Let me ...

Akebia Therapeutics, Inc. ( AKBA) announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for rare complement-mediated kidney diseases, including IgA ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The complement inhibitors are the latest ...

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc. (HKEX:1228), a China and US-based global biopharmaceutical company committed to the research, development and ...

Considerations regarding where newer, novel complement therapies will likely fit into the treatment landscape for patients with cold agglutinin disease. Neil Minkoff, MD: Let me ask you, first on the ...

REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today ...

Complement Therapeutics GmbH (CTx) – a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases – announced the completion of a €72 million Series A ...